Alpha Tau Medical Ltd (DRTS) has released an update.
Alpha Tau Medical Ltd reports its first quarter 2024 financial outcomes, highlighting the initiation of clinical trials for its Alpha DaRT cancer therapy in various cancers and a solid cash reserve of $80.7 million, ensuring operational funding for the next two years. The company is progressing in pivotal trials, such as the ReSTART U.S. trial for cutaneous squamous cell carcinoma, and is preparing for potential future product launches. Promising preclinical data and the treatment of the first patient in liver metastases and prostate cancer trials mark significant strides in the company’s pursuit of innovative cancer treatments.
For further insights into DRTS stock, check out TipRanks’ Stock Analysis page.
